Enliven Therapeutics

ELVN-002 Clin1 NSCLC, solid tumors; undisclosed Clin0 solid tumors; 2 undisclosed programs RD solid tumors

Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule kinase inhibitors for the treatment of various cancers to increase survival and enhance patient well-being. Enliven Therapeutics’ research leverages a combination of clinically validated biological targets, differentiated chemistry, and disciplined clinical trial design to create innovative therapies for unmet needs in cancer treatment. Their pipeline prioritizes potentially best-in-class or first-in-class therapies designed to address critical challenges in cancer treatment. They have two promising lead candidates in their pipeline. Their lead candidate, ELVN-001, is a highly selective small molecule kinase inhibitor designed to target the BCR-ABL gene fusion, the driver mutation in CML. Their other lead candidate, ELVN-002, is a potent and irreversible inhibitor targeting HER2 and pan-HER2 mutant kinases, for the treatment of HER2-positive cancers, including breast and lung cancers.

Jobs: